DNP 004
Alternative Names: DNP-004Latest Information Update: 28 Feb 2024
At a glance
- Originator DiNonA
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Breast-cancer in South Korea (Parenteral)